Overview

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody(Ies) in Adult Healthy Volunteers as Related to COVID

Status:
Not yet recruiting
Trial end date:
2022-12-14
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of REGN15160 in healthy participants, as measured by all treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (SAEs). The secondary objectives of the study are: - To assess the concentration-time profile of REGN15160 in serum - To assess the immunogenicity of REGN15160
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals